ReviewFrontiers in bioengineering and biotechnology2020
Methods to Scale Down Graphene Oxide Size and Size Implication in Anti-cancer Applications.
Review in Frontiers in bioengineering and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Graphene and Graphene Oxide-Based Nanocarriers for Targeted Delivery of Mitoxantrone in Cancer Therapy.International journal of nanomedicine · 2026Review
- Multistage Nanocarrier Based on an Oil Core-Graphene Oxide Shell.Pharmaceutics · 2024Article
- Characteristics of Graphene Oxide for Gene Transfection and Controlled Release in Breast Cancer Cells.International journal of molecular sciences · 2022Review
- Advances in Biologically Applicable Graphene-Based 2D Nanomaterials.International journal of molecular sciences · 2022Review
- High-Yield Production of Nano-Lateral Size Graphene Oxide by High-Power Ultrasonication.Materials (Basel, Switzerland) · 2021Article
- Emerging 2D Nanomaterials for Multimodel Theranostics of Cancer.Frontiers in bioengineering and biotechnology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite considerable progress in the comprehension of the mechanisms involved in the origin and development of cancer, with improved diagnosis and treatment, this disease remains a major public health challenge with a considerable impact on the social and economic system, as well as on the individual. One way to improve effectiveness and reduce side effects is to consider responsive stimuli delivery systems that provide tailor-made release profiles with excellent spatial and temporal control. 2D nanomaterials possess special physicochemical properties (e.g., light, ultrasonic and magnetic responses) and biological behaviors such as endocytosis, biodistribution, biodegradation, and excretory pathways, which lead to their use in various biomedical applications. In particular, among 2D nanomaterials, graphene and its derivatives, namely graphene oxide (GO) nanomaterials, have attracted enormous attention in cancer diagnosis and therapy because they combine, in a unique material, extremely small size, NIR absorption, delocalized electrons, extremely high surface area, and versatile surface functionality. Taking into account the fundamental role played by GO size, in this review, we summarize the main methods employed to reduce and homogenize in nanometric scale the lateral dimensions of graphene oxide produced by chemical exfoliation of graphite, as well as post-synthesis separation techniques to uniform the size. We also discuss the implication of the small size in cancer treatment by exploiting GO nanocarriers as an effective theranostic tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.